46 results about "Anti arthritic" patented technology

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

The invention relates to an Oral Delayed Immediate Release formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids. The invention further relates to formulations containing an Immediate Release formulation combined with one or more Oral Delayed Immediate Release formulations with different lag-times and to a method of preparing an Oral Delayed Immediate Release formulation.The Oral Delayed Immediate Release formulation may be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere compounds, anti-hypertensives, sedatives, anti-depressants, anti-anxiety compounds, cortico-steroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics, anti-aritmics, anti-rheumatics, anti-arthritic compounds and anti-angina compounds.The Oral Delayed Immediate Release formulation may also be used for the application of biological active compounds such as proteins, peptides, enzymes, vaccines and oligonucleotides.

The present invention provides an oral formulation comprising ingredients extracted from Caulis Sinomenii, Radix Aconiti Lateralis Preparata, Radix Paeoniae Alba, Cortex Moutan, and Rhizoma Curcumae Longae. The formulation has anti-arthritic, anti-inflammatory and anti-nociceptive properties and is suitable for the treatment of arthritis, symptoms associated with arthritis and other similar conditions.

The present disclosure is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The disclosure also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

The invention relates to a coumarin compound acidulated by glucal and application thereof. The compound has a structure showed in the right formular, wherein R is one of-H, -OH, -CH3, -OCH3, -NH2 or ester group; and R1, R2, R3 and R4 are one of -H, -OH, -CH3, -SH, -OCH3, -NH2 or glucal acid group. The coumarin compound acidulated by the glucal has the activities of resisting arthritic and tumor.

The present invention is related to pharmaceutical composition essentially comprising herbal extract of Chaenomelis Fructus, Achyranthis Radix, Acanthopanax, Phlomidis Radix, Gentianae Radix, Clematidis Radix, and additionally comprising herbal extract selected from group consisting of Angelicae Radix, Cnidii Rhizoma, Gastrodiae Rhizoma, Safflower, Cinnamomi Cortex, Job's tear, Aurantii nobilis Pericapium, Ledebouriellae Radix, Lonicera japonica, Akebiae caulis, Caragana chamlagu, Licorice root, Notopterygium incisum, Persicae semen, Eucommia ulmoides, Atractylodes Rhizoma, Torilis japonica according to the need for the prevention and treatment of arthritic diseases and methods of using the above extracts and composition as potent anti-inflammatory and anti-arthritic agents.

A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

The invention provides a novel herbal composition for treatment of arthritis and inflammation. The herbal composition comprises a therapeutically effective combination of extracts obtained from the plants Terminalia chebula, Pluchea lanceolata, Desmodium gangeticum, Vitex negunto and Zingiber officinale, optionally along with pharmaceutically acceptable additives. The invention further comprises methods of making the herbal composition and methods of use for the treatment of arthritis and inflammation.

Application of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof in preparing medicine for the treatment of refractory rheumatoid arthritis, and application in medicine for inducing autophagy in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA), in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

The invention relates to the technical field of cells, and particularly discloses an application of mesenchymal stem cell-derived small extracellular vesicles to preparation of drugs for treating autoimmune diseases. The mesenchymal stem cell-derived small extracellular vesicles provided by the invention have the advantages of extremely low immunogenicity, small side effects, small rejection immune response, stability in a living body, natural homing and targeting properties and long residence time, the mesenchymal stem cell-derived small extracellular vesicles are made into drugs which have avery good treatment effect on rheumatoid arthritis, and arthritis can be effectively resisted.

Chromium-three cation in combination with Phyllanthus emblica extract and Shilajit is useful in treating symptoms associated with osteoarthritis including reduction of inflammation and pain in a mammal, particularly a human or an animal. The combination shows significant reduction in overall pain levels and other pain measures in a canine model, and in human studies. Thus the composition is an anti-arthritic formulation that decreases pain and inflammation.

The invention belongs to the technical field of polymer chemistry, biomedical materials and pharmacy, and discloses a targeted controlled-release anti-arthritis medicinal preparation and a preparationmethod thereof. The pharmaceutical preparation is a drug-loaded micelle, the drug-loaded micelle is composed of a segmented copolymer PEG-PPS and tripterine, and the tripterine is loaded in the micelle formed by the segmented copolymer PEG-PPS. The preparation method comprises the following preparation steps: (1) dissolving 20-80 parts by mass of PEG-PPS and 1-10 parts by mass of tripterine in 5-10 parts by volume of tetrahydrofuran; and (2) under ultrasonic dispersion, adding the solution obtained in the step (1) into 50-100 parts by volume of water, carrying out vacuum distillation to remove tetrahydrofuran, and carrying out repeated ultrafiltration and sterile microporous filtration membrane filtration to obtain the anti-arthritis nano-drug preparation. The medicinal preparation disclosed by the invention is sensitive to rheumatoid arthritis inflammation, controllable release of the medicine can be realized, and joint synovitis and bone erosion can be obviously inhibited.

The invention discloses a diclofenac-glycine-resveratrol conjugate, a preparation method and an application. The conjugate is formed by coupling glycine serving as a linking arm with diclofenac and resveratrol respectively; diclofenac and glycine are linked by an amido bond; a diclofenac-glycine conjugate is linked with resveratrol by multiple sites of ester bonds. Due to introduction of glycine,the solubility of the conjugate is increased, due to introduction of diclofenac and resveratrol, the anti-arthritis effect of the conjugate is significantly enhanced, adverse reactions are reduced, and safety is higher. The synthesis method of the conjugate is simple and suitable for industrial production.